Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Genotypes and haplotypes in the insulin-like growth factors, their receptors and binding proteins in relation to plasma metabolic levels and mammographic density.

Biong M, Gram IT, Brill I, Johansen F, Solvang HK, Alnaes GI, Fagerheim T, Bremnes Y, Chanock SJ, Burdett L, Yeager M, Ursin G, Kristensen VN.

BMC Med Genomics. 2010 Mar 19;3:9. doi: 10.1186/1755-8794-3-9.

2.
3.

Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women.

Bremnes Y, Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT.

Int J Cancer. 2007 Dec 1;121(11):2506-11.

4.

Insulin-like growth factor and mammographic density in postmenopausal Norwegian women.

Bremnes Y, Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):57-62.

5.

Different types of postmenopausal hormone therapy and mammographic density in Norwegian women.

Bremnes Y, Ursin G, Bjurstam N, Lund E, Gram IT.

Int J Cancer. 2007 Feb 15;120(4):880-4.

6.

Plasma levels of leptin and mammographic density among postmenopausal women: a cross-sectional study.

Stuedal A, Ursin G, Veierød MB, Bremnes Y, Reseland JE, Drevon CA, Gram IT.

Breast Cancer Res. 2006;8(5):R55.

7.

Plasma levels of enterolactone and percentage mammographic density among postmenopausal women.

Stuedal A, Gram IT, Bremnes Y, Adlercreutz H, Veierød MB, Ursin G.

Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2154-9.

8.

Percentage density, Wolfe's and Tabár's mammographic patterns: agreement and association with risk factors for breast cancer.

Gram IT, Bremnes Y, Ursin G, Maskarinec G, Bjurstam N, Lund E.

Breast Cancer Res. 2005;7(5):R854-61. Epub 2005 Aug 25.

9.

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.

Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G.

J Clin Oncol. 2005 Aug 1;23(22):5126-37. Epub 2005 Jun 27.

PMID:
15983390
10.

[Should complementary therapies be offered in hospitals?].

Risberg T, Bremnes Y, Kolstad A, Holte H, Wist E, Mella O, Klepp O.

Tidsskr Nor Laegeforen. 2004 Dec 2;124(23):3078-80. Norwegian.

11.

Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.

Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I.

Acta Oncol. 2004;43(2):186-9.

PMID:
15163168
12.

Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway.

Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, Klepp O, Wilsgaard T, Cassileth BR.

Eur J Cancer. 2004 Mar;40(4):529-35.

PMID:
14962719
13.

Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway.

Kolstad A, Risberg T, Bremnes Y, Wilsgaard T, Holte H, Klepp O, Mella O, Wist E.

Support Care Cancer. 2004 May;12(5):312-8. Epub 2004 Feb 6.

PMID:
14767750
14.

Supplemental Content

Loading ...
Support Center